



Paclitaxel nano-conjugated to polyhedral oligomeric silsesquioxane (POSS) nanoparticles as a novel water-soluble prodrug

Jafar Rezaie^a, Nasrollah Jabbari^a, Sadegh Asghari Kalashani^b, Esmail Jabbari^{c,*}, Ali Akbari^{a,*}

^a Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran

^b Department of Medical Laboratory Sciences, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran

^c Department of Chemical Engineering, University of South Carolina, Columbia, SC, USA

ARTICLE INFO

Keywords:

Polyhedral oligomeric silsesquioxanes
Nanoparticles
Paclitaxel
Functional
Nanoconjugate

ABSTRACT

Condensed polyhedral oligomeric silsesquioxane (POSS) family of materials are very attractive as a nanoscale drug delivery system in cancer therapy. This work describes a novel method for conjugation of poorly soluble anticancer drug paclitaxel (PTX) to octa-aminopropyl polyhedral oligomeric silsesquioxane hydrochloride salt nanoparticles (OA-POSS NPs). The synthesized nanoconjugate of PTX and OA-POSS NPs (PTX_n-OA-POSS_{8-n} prodrug) was fully soluble in aqueous solution as compared to the free PTX.

1. Introduction

Paclitaxel (PTX) is a member of the taxane family of compounds extracted from the bark of the Pacific yew tree *Taxus brevifolia* [1]. PTX is widely used as an anticancer drug against a wide range of cancers including breast, ovarian and lung cancers. However, the effectiveness of PTX as an anticancer drug is limited by its low solubility in aqueous physiological medium (5.56×10^{-3} g/L) as well as its low permeability in the tumor tissue [2]. In this regard, formulation based on a mixture of Cremophor EL and dehydrated ethanol (50:50, v/v) known as Taxol® (Bristol-Myers Squibb) was developed. Due to its some adverse side effects corresponded to Cremophor EL and dehydrated ethanol, there is an immediate need for the expansion of new alternative PTX formulations [3]. Polymeric nanoparticles (NPs) and dendrimers have been used extensively for encapsulation or conjugation of anticancer agents to increase the drug's residence time in circulation and sustained drug release in the tumor tissue [4,5]. However, the use of polymeric NPs in cancer therapy is limited by polydispersity and dendrimers require a multistep synthetic process. NPs based on oligomers of symmetric nanostructured silsesquioxane (POSS), with their high water solubility and ease of functionalization, can overcome the shortcomings of polymeric NPs and dendrimers as a carrier in drug delivery [6]. Moreover, POSS NPs possess the ability to penetrate cell membranes which is important in drug delivery to tumor cells [7]. Here we report on a novel, one-step method to functionalize multiple arms of OA-POSS with PTX to produce the PTX_n-OA-POSS_{8-n} nanoconjugate, as a water-soluble PTX

prodrug.

2. Experimental section

2.1. Chemicals and instruments

The chemicals and instruments used in this work are described in [Supporting Information](#) file S1.

2.2. Synthesis of OA-POSS NPs

The procedure for the synthesis of OA-POSS NPs is provided in [Supporting Information](#) file S2.

2.3. Synthesis of PTX-COOH (Taxol-2'-hemisuccinate)

Taxol-2'-hemisuccinate was synthesized according to a procedure previously described [8]. Briefly, in a 25 ml round bottom flask containing 270 mg of Taxol (PTX) and 38 mg of succinic anhydride (SA) in 13 ml of CH₂Cl₂, 36 μL (10-fold molar excess) of dry pyridine was added at ambient temperature and stirred for 3 days. The progress of the reaction was monitored by TLC (ethyl acetate–hexane, 1:1, v/v). After the reaction, the solvent was evaporated under vacuum, the residue was dissolved in CH₂Cl₂ (5 ml), and the product (Taxol-2'-hemisuccinate) was purified by silica gel column chromatography (ethyl acetate–hexane, 1:1, v/v) to provide 258 mg of product (86%).

* Corresponding authors.

E-mail address: akbari.a@umsu.ac.ir (A. Akbari).

<https://doi.org/10.1016/j.matlet.2021.131013>

Received 29 March 2021; Received in revised form 25 August 2021; Accepted 1 October 2021

Available online 8 October 2021

0167-577X/© 2021 Elsevier B.V. All rights reserved.




Fig. 1. The synthesis of water-soluble prodrug PTX_n -OA-POSS $_{8-n}$.




Fig. 2. (A) MALDI-TOF spectrum, (B) FTIR spectrum, (C) TEM image and (D) the corresponding TEM-elemental images of PTX_n -OA-POSS $_{8-n}$ nanoconjugates.

2.4. Synthesis of water-soluble PTX_n -OA-POSS $_{8-n}$ nanoconjugate

PTX-COOH (50 mg, 50 μ mol), triethylamine (30 μ L) and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM, 20 mg, 60 μ mol) were stirred in 2 ml dry DMSO until the solid was completely dissolved. To the mixture solution, OA-POSS (20 mg, 17 μ mol) was added. The mixture was stirred at ambient temperature under argon atmosphere. After stirring for 24 h, the resulting mixture was poured into acetonitrile (45 ml) containing 0.1% HCl, vortexed, precipitated, and collected by vacuum filtration.

3. Results and discussion

3.1. Synthesis and characterization of materials

OA-POSS was synthesized by hydrolysis and condensation of 3-aminopropyltriethoxysilane (APTES) in acidic medium at 90 $^{\circ}$ C [9]. Paclitaxel (PTX) was reacted with succinic anhydride in the presence of catalytic amount of pyridine for functionalization with carboxy groups (PTX-COOH) and formation of an ester bond (cleavable by enzymes) at

the C2' position [8]. The PTX_n -OA-POSS $_{8-n}$ nanoconjugate was synthesized by conjugating the water-soluble OA-POSS NPs with PTX-COOH using DMT-MM as a coupling reagent, as depicted in Fig. 1.

The formation of OA-POSS, PTX-COOH and PTX_n -OA-POSS $_{8-n}$ was confirmed by MALDI-TOF MS. The presence of two sharp peaks at m/z 2753 and 3688 in the mass spectra (Fig. 2A), which were assigned to PTX_2 -OA-POSS $_6$ (calculated theoretical molecular weight (MW) 2753) and PTX_3 -OA-POSS $_5$ (calculated theoretical MW 3689) nanoconjugates, respectively, confirmed the successful conjugation of two or three PTX molecules to OA-POSS NPs. The molecular peaks at m/z 881 (calculated theoretical MW 881) and 954 (calculated theoretical MW 953.9) in MS spectra of Figs. S1 and S2 confirmed the formation of OA-POSS and PTX-COOH, respectively. The chemical composition of the synthesized PTX_n -OA-POSS $_{8-n}$ was studied by FTIR spectroscopy. The appearance of a new peak at 1589 cm^{-1} in the FTIR spectrum of PTX_n -OA-POSS $_{8-n}$ (Fig. 2B), which is related to the amide bond vibration, confirmed the conjugation of PTX-COOH to OA-POSS. The presence of two other new characteristic peaks at 1436 cm^{-1} and 720 cm^{-1} , which were assigned to the $-C=C-$ stretching vibration of benzene ring of PTX [8], further confirmed successful conjugation of PTX-COOH to OA-POSS. In addition, the Si-O-Si




Fig. 3. ^1H NMR spectra of OA-POSS (in D_2O), PTX (in $\text{DMSO}-d_6$), PTX-COOH (in $\text{DMSO}-d_6$) and $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugate (in D_2O).

asymmetric stretching absorption between 1110 and 1125 cm^{-1} persisted as the most prominent peak of POSS cage in the spectrum of $\text{PTX}_n\text{-OA-POSS}_{8-n}$ [10]. The morphology of OA-POSS and $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugates was further studied by TEM analysis as shown in Fig. S3 and Fig. 2C, respectively. From Fig. S3, OA-POSS cores are apparent as dark spots with dimeters in the range of $5\text{--}10\text{ nm}$ [11]. However, the mean size of the $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugates increased due to high aggregation tendency. The nanoconjugates had a spherical shape with an average size of $20\text{--}30\text{ nm}$. The elemental mapping images (Fig. 2D) reveal the existence of C, N, O, Si and Cl elements in $\text{PTX}_n\text{-OA-POSS}_{8-n}$.

^1H NMR spectra of OA-POSS, PTX, PTX-COOH and $\text{PTX}_n\text{-OA-POSS}_{8-n}$ are shown in Fig. 3. ^1H NMR spectrum of OA-POSS shows three sharp peaks with chemical shifts at 0.72 , 1.67 and 2.90 ppm corresponding to Si-CH_2 , $-\text{CH}_2$ and $-\text{CH}_2\text{-N-}$ methylene groups, respectively [9]. The ^1H NMR spectrum of PTX-COOH showed the characteristic peaks centered at 2.6 ppm which corresponded to $-\text{CH}_2\text{CH}_2-$ group of the succinic anhydride. In addition, the characteristic peak of $\hat{2}\text{-H}$ of PTX at 4.70 ppm was shifted to 5.95 ppm in PTX-COOH [8]. As compared with the ^1H NMR spectrum of OA-POSS, the aromatic chemical shifts at $7.2\text{--}8.0\text{ ppm}$ in the spectrum of $\text{PTX}_n\text{-OA-POSS}_{8-n}$ corresponded to the benzene ring of PTX. These results confirmed successful synthesis of the water-soluble $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugate.

For the stability study, $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugate was dissolved in distilled water and stored at room temperature. DLS result which is in good accordance with TEM results showed no remarkable change in the hydrodynamic particle size of $\text{PTX}_n\text{-OA-POSS}_{8-n}$ after 14 days (Fig. S4). This means that there is no physical association in $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugate, which guaranteed its high stability in distilled water. Finally, the solubility of $\text{PTX}_n\text{-OA-POSS}_{8-n}$ in water was examined and found to be 0.65 mg/mL which was significantly higher than PTX solubility in water ($<0.004\text{ mg/mL}$) [12].

4. Conclusion

A simple one-step reaction between OA-POSS NPs bearing amino groups and PTX-COOH in the presence of a coupling agent was successfully used to synthesize the $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugate as a novel water-soluble prodrug. MOLDI-TOF analysis of the product confirmed conjugation of two or three PTX molecules to OA-POSS NPs. The $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugates had a spherical shape and a size distribution in the range of $20\text{--}30\text{ nm}$, as shown in TEM images. This work provides a POSS nano-building framework for modification of anticancer drugs to their water-solubility. Taken together, this work reports a novel and efficient method for the synthesis of water-soluble $\text{PTX}_n\text{-OA-POSS}_{8-n}$ nanoconjugate prodrug for application in cancer therapy. The evaluation of $\text{PTX}_n\text{-OA-POSS}_{8-n}$ as an anticancer prodrug against human cancer cells is in progress.

CRediT authorship contribution statement

Jafar Rezaie: Visualization, Investigation. **Nasrollah Jabbari:** Formal analysis, Investigation. **Sadegh Asghari Kalashani:** Visualization, Investigation. **Esmail Jabbari:** Formal analysis, Writing – review & editing. **Ali Akbari:** Conceptualization, Supervision, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

We thank Urmia University of Medical Sciences for providing financial support. (Project number: 9613, approved by the Research Ethics Committee at the Urmia University of Medical Sciences, Ethical code: IR.UMSU.REC.1398.274).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.matlet.2021.131013>.

References

- [1] H. Xiao, P. Verdier-Pinard, N. Fernandez-Fuentes, B. Burd, R. Angeletti, A. Fiser, S. B. Horwitz, G.A. Orr, Insights into the mechanism of microtubule stabilization by Taxol, *Proc. Natl. Acad. Sci.* 103 (27) (2006) 10166–10173.
- [2] Y. Tian, H. Zhang, Y. Qin, D. Li, Y. Liu, H. Wang, L.i. Gan, Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria, *Drug Dev. Ind. Pharm.* 44 (12) (2018) 2071–2082.
- [3] B.A. Weaver, W. Bement, How Taxol/paclitaxel kills cancer cells, *Mol. Biol. Cell* 25 (18) (2014) 2677–2681.
- [4] K. Luo, S. Yin, R. Zhang, H. Yu, G. Wang, J. Li, Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy, *Int. J. Pharm.* 589 (2020), 119870.
- [5] N. Li, H. Cai, L. Jiang, J. Hu, A. Bains, J. Hu, Q. Gong, K. Luo, Z. Gu, Enzyme-sensitive and amphiphilic PEGylated dendrimer-paclitaxel prodrug-based nanoparticles for enhanced stability and anticancer efficacy, *ACS Appl. Mater. Interfaces* 9 (8) (2017) 6865–6877.
- [6] M. Fegghi, J. Rezaie, A. Akbari, N. Jabbari, H. Jafari, F. Seidi, S. Szafert, Effect of multi-functional polyhydroxylated polyhedral oligomeric silsesquioxane (POSS) nanoparticles on the angiogenesis and exosome biogenesis in human umbilical vein endothelial cells (HUVECs), *Mater. Des.* 197 (2021), 109227.
- [7] C. McCusker, J.B. Carroll, V.M. Rotello, Cationic polyhedral oligomeric silsesquioxane (POSS) units as carriers for drug delivery processes, *Chemical Communications* (8) (8) (2005) 996, <https://doi.org/10.1039/b416266h>.
- [8] T. Yin, J. Wang, L. Yin, L. Shen, J. Zhou, M. Huo, Redox-sensitive hyaluronic acid-paclitaxel conjugate micelles with high physical drug loading for efficient tumor therapy, *Polym. Chem.* 6 (46) (2015) 8047–8059.

- [9] A. Akbari, A. Naderahmadian, B. Eftekhari-Sis, Silver and copper nanoparticles stabilized on ionic liquids-functionalized polyhedral oligomeric silsesquioxane (POSS): Highly active and recyclable hybrid catalysts, *Polyhedron* 171 (2019) 228–236.
- [10] H. Mori, M.G. Lanzendörfer, A.H.E. Müller, J.E. Klee, Silsesquioxane-based nanoparticles formed via hydrolytic condensation of organotriethoxysilane containing hydroxy groups, *Macromolecules* 37 (14) (2004) 5228–5238.
- [11] M. Janeta, L. John, J. Ejfler, S. Szafert, High-Yield Synthesis of Amido-Functionalized Polyoctahedral Oligomeric Silsesquioxanes by Using Acyl Chlorides, *Chemistry–A, European Journal* 20 (48) (2014) 15966–15974.
- [12] H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, *Eur. J. Cancer* 37 (13) (2001) 1590–1598.